Clinicopathological correlations in a series of adult patients with non-alcoholic fatty liver disease

被引:12
|
作者
Fotiadu, Anastasia [1 ]
Gagalis, Asterios [2 ]
Akriviadis, Evangelos [2 ]
Kotoula, Vassiliki [1 ]
Sinakos, Emmanouil [2 ]
Karkavelas, Georgios [1 ]
Hytiroglou, Prodromos [1 ]
机构
[1] Aristotle Univ Thessaloniki, Sch Med, Dept Pathol, GR-54006 Thessaloniki, Greece
[2] Aristotle Univ Thessaloniki, Sch Med, Dept Internal Med, GR-54006 Thessaloniki, Greece
关键词
aminotransferases; fatty liver; microgranulomas; non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; PATHOLOGICAL FEATURES; STEATOHEPATITIS;
D O I
10.1111/j.1440-1827.2009.02489.x
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Possible correlations among clinical data, serum aminotransferase levels and histological features were assessed in a series of 37 adult patients with non-alcoholic fatty liver disease (NAFLD), consisting of nine patients with fatty liver (FL) and 28 with non-alcoholic steatohepatitis (NASH). In each liver biopsy, the NAFLD activity score (NAS) and the stage of fibrosis were determined. Additionally, the number of Kupffer cell aggregates (microgranulomas) per centimeter of biopsy length (MG/cm ratio) was assessed on immunohistochemical stains for CD68 antigen. Definite NASH (NAS >= 3 5) was strongly correlated with serum aspartate aminotransferase (AST) level (P = 0.003), stage of fibrosis (P = 0.003) and age (P = 0.014). On multivariate analysis, age > 46 years and AST level above normal values were found to be independent clinical predictors of established NASH. The MG/cm ratio increased from control liver to FL to NASH (P < 0.001), and was correlated with the NAS (P = 0.003) and with the stage of fibrosis (P = 0.004), but not with the serum aminotransferase levels. In conclusion, persistent AST elevation in patients with suspected NAFLD should be an indication for liver biopsy, in order to determine the severity of necroinflammatory activity and the stage of fibrosis. Microgranuloma counting may represent a useful complementary marker of necroinflammatory activity in patients with NAFLD.
引用
收藏
页码:87 / 92
页数:6
相关论文
共 50 条
  • [21] Non-alcoholic fatty liver disease
    Carreras, MP
    Tortajada, GC
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2005, 97 (05) : 377 - 377
  • [22] Non-alcoholic fatty liver disease
    Bjornsson, Einar
    Angulo, Paul
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2007, 42 (09) : 1023 - 1030
  • [23] Non-alcoholic fatty liver disease
    Cua, IHY
    George, J
    HOSPITAL MEDICINE, 2005, 66 (02): : 106 - 111
  • [24] Non-alcoholic fatty liver disease
    Tuyama, Ana C.
    Chang, Charissa Y.
    JOURNAL OF DIABETES, 2012, 4 (03) : 266 - 280
  • [25] Non-alcoholic fatty Liver disease
    Calderaro, Julien
    Zafrani, Elie Serge
    ANNALES DE PATHOLOGIE, 2010, 30 (06) : 413 - 420
  • [26] Non-alcoholic fatty liver disease
    Farrell, Geoffrey C.
    Wardell, Rebecca
    Teoh, Narci
    Chitturi, Shiv
    INTERNAL MEDICINE JOURNAL, 2019, 49 (05) : 681 - 683
  • [27] Non-alcoholic fatty liver disease
    Adams, LA
    Angulo, P
    LIVER DISEASES: ADVANCES IN TREATMENT AND PREVENTION: IN HONOUR OF HANS POPPER'S 100TH BIRTHDAY, 2004, 137 : 250 - 270
  • [28] Non-Alcoholic Fatty Liver Disease
    Engin, Atilla
    OBESITY AND LIPOTOXICITY, 2017, 960 : 443 - 467
  • [29] Non-alcoholic fatty liver disease
    Brent A. Neuschwander-Tetri
    BMC Medicine, 15
  • [30] Non-alcoholic fatty liver disease
    Alba, LM
    Lindor, K
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (08) : 977 - 986